Estrogens second-generation effects

Resistance to tamoxifen is a complex phenomenon and there is evidence that relapse under tamoxifen therapy is linked to the estrogenicity of the drug. Both, the great success of tamoxifen and its liabilities have boosted the search for new analogues in the past 25 years with the goal of identifying a compoimd with increased anti-tumour activity and with reduced side effects. A second generation of structurally related triphenyl-ethylenes like... 

Estrogen replacement (see p. 264) is the most effective therapy for the prevention of postmenopausal bone loss. When initiated in the immediate postmenopausal period, estrogen prevents osteoporosis and reduces the risk of hip fracture. Raloxifene, a second-generation selective estrogen receptor modulator (see p. xxx), increases women s bone density without increasing the risk for endometrial cancer. In addition, raloxifene has recently been reported to decrease the risk of estrogen receptor-positive breast cancer. 

---